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Various forms of immunotherapy utilizing bacille
Calmette-GueÂrin vaccine or vaccinia vaccine have
been evaluated in clinical trials on melanoma
patients. The effect of the ``natural'' application of
these vaccinations, administered to provide protec-
tion against tuberculosis and smallpox, has, however,
never been studied in epidemiologic investigations
on risk factors for melanoma. In a case±control
study comprising 11 institutions in seven countries
we recruited 603 incident melanoma cases and 627
population controls frequency matched to the cases
with respect to sex, age, and ethnic origin within
each center to assess this relationship to obtain
insights into the prevention of melanoma. Exposure
information, incorporating also detailed ascertain-
ment of potential confounding variables, was
obtained in standardized personal interviews at the
study subject's home. We found an inverse associ-
ation between melanoma risk and previous bacille
Calmette-GueÂrin vaccine/vaccinia vaccination
depicted by an adjusted odds ratio of 0.44 (95% con-
®dence interval: 0.26±0.72) for those vaccinated
against tuberculosis and smallpox compared with
subjects without a positive history of either vaccin-
ation. A variety of subgroup analyses showing a con-
sistent pattern of results make it unlikely that the
observed inverse association is a spurious ®nding.
We conclude that bacille Calmette-GueÂrin vaccin-
ation and vaccinia vaccination may lower melanoma
risk. Current immunologic theory of melanoma
development provides a sound basis for understand-
ing the biologic plausibility of the ®ndings that have
to be con®rmed in future studies. Key words: bacille
Calmette-GueÂrin vaccine/case±control studies/epidemi-
ology/melanoma/smallpox vaccine. J Invest Dermatol
119:570±575, 2002
E
pidemiologic investigations on potential determinants
of the risk of developing malignant melanoma of the
skin run into the hundreds (Berwick, 1998). As the
incidence rate of melanoma has increased steadily in
most Caucasian populations throughout the world for
several decades (Swerdlow, 1990), the disease has attracted a
considerable amount of epidemiologic attention. The role of
cutaneous factors, such as skin type and number of nevi as well as
exposure to ultraviolet radiation (UVR) have been studied most
intensively, but also a variety of other factors less obviously related
to this type of skin cancer have been scrutinized epidemiologically
(Berwick, 1998). Given the intensive efforts to treat melanoma by
various forms of immunotherapy utilizing bacille Calmette-GueÂrin
(BCG) vaccine or vaccinia vaccine during the past decades,
surprisingly only one study so far has examined the association
between vaccination history and melanoma risk focusing on
in¯uenza vaccination (Mastrangelo et al, 2000).
The ®rst published use of BCG as a cancer vaccine dates back to
Holmgren in 1935 in Switzerland, but it was not until the late
1950s and 1960s that clinical and experimental studies generated
enthusiasm for its use against various cancers, including melanoma
(Crispen, 1989). Promising results of animal experiments in guinea
pigs (Zbar et al, 1972) stimulated a variety of therapeutic trials,
initially on small numbers of patients. These early, mostly
uncontrolled, studies supported the use of BCG as an effective
melanoma therapy, but later controlled studies on large numbers of
patients did not con®rm these results. In a pooled analysis of its
ef®cacy, Tan and Ho (1993) identi®ed 20 randomized controlled
clinical trials where one of the therapeutic regimens consisted of
BCG vaccination. The results of these trials were very variable and
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did not convincingly demonstrate a real bene®cial effect of BCG
immunotherapy. Consequently, interest in this form of melanoma
therapy and further research in this area has declined during recent
years.
Experience with vaccinia vaccination as a therapeutic agent for
melanoma is less advanced. Four groups reported in the 1970s on
rather small studies consisting of mostly melanoma patients with
metastatic disease receiving vaccinia vaccination (Herrmann et al,
1970; Hunter-Craig et al, 1970; Roenigk et al, 1974; Everall et al,
1975). Overall, the therapeutic success was limited to a few patients
and the response to treatment was transient. Therefore, this
approach to melanoma therapy is no longer in use.
Although there is quite a difference between immunologic
prevention of melanoma and immunotherapy of an established
lesion, we found it tempting to analyze epidemiologically whether
these vaccinations in¯uence melanoma risk. In the population-
based case±control study FEBIM (Effect of FEBrile Infectious
disease and vaccinations on malignant Melanoma) we investigated
the relationship between the occurrence of melanoma and the
``natural'' application of BCG vaccination, administered to the
new-born to provide protection against tuberculosis, and vaccinia
vaccination, administered twice to children to provide protection
against smallpox until the late 1970s. The FEBIM study protocol
described the rationale for this planned analysis that was performed
with the a priori hypothesis of an inverse association between these
vaccinations and melanoma development. Here, we report the
results of the analyses considering the separate and joint effects of
both vaccinations on melanoma risk.
MATERIALS AND METHODS
Design and participants The FEBIM study has been designed as a
multicenter case±control study of 11 collaborating institutions in seven
European countries under the auspices of the Melanoma Cooperative
Group of the European Organization for Research and Treatment of
Cancer. Details on the design and conduct of the FEBIM study have
been published elsewhere (KoÈlmel et al, 1999). Brie¯y, the study sample
consisted of 603 incident cases with histopathologically veri®ed diagnosis
of malignant melanoma of the skin and 627 population controls
frequency matched to the cases with respect to sex, age, and ethnic
origin within each center. The control group comprised individuals
without a previous history of cancer of any type who were randomly
chosen from the same municipalities as the cases. The practical
implementation of the population-based sampling of controls varied
between the centers depending on local conditions. Only some centers
could realize a strict strati®ed random sampling of controls from
population rosters. The majority of centers used a prespeci®ed random
procedure of selecting houses situated in neighboring streets of the cases'
home to contact potential controls in the population. Such a method of
neighborhood sampling offers a practical solution to the problem of
selecting population controls where population rosters are not accessible.
The recruitment period for the investigation lasted from 1994 to 1997.
The participation rates among eligible cases and controls were 81.2% and
85.0%, respectively.
Table I. The relationship between vaccination against tuberculosis (BCG) and melanoma risk. Results of a separate analysis in
the total sample and in strata depending on sex, age, and tumor thickness
Stratum
Sample size of Positive history of vaccination among
Cases (n) Controls (n) Cases (n) Controls (n) Adjusted ORa 95% CI
Total sample 603 627 290 367 0.67 0.51±0.89
Sex
Males 277 236 128 152 0.68 0.44±1.05
Females 326 364 162 215 0.66 0.46±0.96
Age
< 50 y 198 257 132 192 0.69 0.42±1.18
> 50 y 405 370 158 175 0.67 0.47±0.94
Tumor thicknessb
< 1.5 mm 307 627 138 367 0.70 0.50±0.99
> 1.5 mm 250 627 128 367 0.57 0.38±0.83
aAdjusted for centre, sex, age, ethnic origin, skin type, freckling index, number of nevi, and number of sunburns.
bIn 46 cases the information on tumor thickness was not available.
Table II. The relationship between vaccination against smallpox (vaccinia) and melanoma risk. Results of a separate analysis
in the total sample and in strata depending on sex, age, and tumor thickness
Stratum
Sample size of Positive history of vaccination among
Cases (n) Controls (n) Cases (n) Controls (n) Adjusted ORa 95% CI
Total sample 603 627 521 564 0.65 0.43±0.96
Sex
Males 277 263 238 243 0.59 0.31±1.11
Females 326 364 283 321 0.65 0.38±1.11
Age
< 50 y 198 257 178 132 0.62 0.28±1.33
> 50 y 405 370 343 332 0.62 0.37±1.01
Tumor thicknessb
< 1.5 mm 307 627 267 564 0.76 0.47±1.25
> 1.5 mm 250 627 216 564 0.58 0.34±0.99
aAdjusted for centre, sex, age, ethnic origin, skin type, freckling index, number of nevi, and number of sunburns.
bIn 46 cases the information on tumor thickness was not available.
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Exposure assessment In a standardized personal interview trained
personnel with a medical background ascertained detailed information on
socio-economic and life-style variables as well as on a variety of
established risk factors for melanoma (for details see KoÈlmel et al, 1999).
All personal interviews were conducted at the study subject's home and
typically lasted for 45 min. In particular, interviewers asked study subjects
speci®cally for their personal history of BCG vaccination against
tuberculosis and vaccinia vaccination against smallpox during childhood.
Answers were veri®ed by the interviewers by inspection of the subjects'
vaccination cards where possible. Furthermore, typical acute adverse
reactions after vaccination against smallpox, including fever, malaise, and
lymphadenopathy, were assessed for all subjects with a positive history of
vaccinia vaccination.
Statistical analysis Logistic regression analysis was employed to
analyze the effect of the two different vaccinations on melanoma risk in
separate and joint logistic models. Confounding variables included in all
models were study center, sex, age, ethnic origin, skin type [according to
Fitzpatrick's classi®cation (Fitzpatrick, 1988)], freckling index (according
to the charts described by Gallagher et al, 1990), number of nevi, and
number of sunburns. We also considered the potentially confounding
effect of the two socio-economic factors, education and employment
status, as well as the variable ``number of febrile infections'', which
showed a signi®cant effect on melanoma risk in our earlier FEBIM
analysis (KoÈlmel et al, 1999). We observed, however, virtually no
confounding by these factors and excluded them from further
consideration.
The strategy for the analysis was as follows: ®rst, we analyzed the
effect of the different vaccinations in two separate logistic models, each
of which comprised a dichotomous exposure variable for the speci®c
vaccination under study. Then, to address the combined effect of both
vaccinations we ®tted a joint logistic model in which both exposure
variables together with their interaction and all the confounders were
incorporated. In this model, the vaccination history can be viewed as a
status variable with four categories: neither vaccinated with BCG nor
with vaccinia (reference category), only vaccinated with BCG but not
with vaccinia, only vaccinated with vaccinia but not with BCG, and
vaccinated with both BCG and vaccinia.
In addition, we considered the in¯uence of the exposure variables in
different subgroups of the study sample de®ned by the variables study
center (eight regions), sex (males, females), age (< 50 y, > 50 y), and
tumor thickness according to Breslow's method (< 1.5 mm, > 1.5 mm)
to investigate potential effect modi®cation. The subgroup analyses
followed the same strategy as employed in the total sample.
Results of the logistic regression analyses are given by the estimates of
the adjusted odds ratios (OR) for the corresponding exposure variables
related to vaccination status and their accompanying 95% con®dence
intervals (CI) obtained by the pro®le likelihood method (Venzon and
Moolgavkar, 1988). All statistical analyses were performed by means of
validated programs within the SAS software (SAS Institute Inc., Cary,
NC).
RESULTS
The FEBIM study sample of 603 cases (277 males, 326 female,
median age: 57 y) and 627 controls (263 males, 364 females,
median age: 55 y) has been described with respect to the
distribution of socio-economic factors and clinical features of the
tumor as well as the relationship between known risk factors and
melanoma occurrence in previous publications (KoÈlmel et al, 1999;
Pfahlberg et al, 2000, 2001).
The results of the separate analyses concerning the relationship
between the two vaccinations and melanoma risk are shown in
Table I (BCG vaccination) and Table II (vaccinia vaccination).
For both vaccinations we found a similar signi®cant reduction in
melanoma risk (OR = 0.67, 95% CI: 0.51±0.89 for BCG and
OR = 0.65, 95% CI: 0.43±0.96 for vaccinia, respectively). No
remarkable differences in risk reduction depending on the subjects'
sex, age, and tumor thickness were apparent.
The results of the joint analysis presented in Table III
con®rmed and further corroborated the inverse association
between the two vaccinations and melanoma occurrence.
Compared with those subjects without either vaccination, we
observed signi®cantly lower melanoma risks for those having
only been vaccinated against tuberculosis (OR = 0.43, 95% CI:
0.20±0.92), having only been vaccinated against smallpox T
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(OR = 0.58, 95% CI: 0.35±0.96), and having been vaccinated
against both tuberculosis and smallpox (OR = 0.44, 95% CI:
0.26±0.72). Thus, in the total sample, the effect of the BCG
vaccination could not be augmented by an additional vaccinia
vaccination.
Whereas similar observations hold true for the subgroups of male
and female subjects, respectively, a pronounced discrepancy
between the two groups de®ned by the subjects' age was apparent.
In the younger (< 50 y) group the risk reductions associated with
the vaccinations were much stronger than in the older (> 50 y)
group (OR of 0.23, 0.31, and 0.27, respectively, for BCG only,
vaccinia only and both BCG and vaccinia vs 0.75, 0.69, and 0.48,
respectively). In addition, in the older group the combination of
both vaccinations had a more distinct effect than the single
vaccinations.
When comparing the results of the analyses for the two case
groups de®ned by the tumor thickness (both evaluated against the
entire control group) a stronger effect of a positive vaccination
history can consistently be seen in the analysis of the subgroup of
cases with thicker (> 1.5 mm) melanomas.
When contrasting the results from the joint analysis (Table III)
with those from the separate analyses (Table I and Table II,
respectively) it becomes evident that the effect of each single
vaccination on melanoma risk is not independent from the other.
We clearly see a lower OR for both vaccinations in the joint
analysis, which can methodologically be explained by the
different de®nition of the reference category in the two analyses.
As the group of subjects without either vaccination exhibits the
highest melanoma risk, the joint analysis shows the risk-lowering
effect of the two vaccinations much clearer than the separate
analyses where the reference category for one vaccination always is
contaminated with subjects with a positive history of the other
vaccination.
Typical acute adverse reactions (fever, malaise, or swollen lymph
nodes) after vaccination against smallpox were reported by 54 cases
and 72 controls. A substantial proportion of study subjects (27% of
the cases with a positive history of vaccination and 24% of the
corresponding controls) could not remember whether they
experienced such adverse reactions or not. This hampered a more
detailed analysis differentiating between the effects of vaccinia
vaccination with and without an adverse reaction. In the remaining
sample of 459 cases and 488 controls with available exposure
information, the combination of BCG and vaccinia vaccination
with some adverse reactions showed a slightly lower OR of 0.33
(95% CI: 0.17±0.67) than the combination of the two vaccinations
without a reaction (OR = 0.37, 95% CI: 0.21±0.61). We did not
attempt further subgroup analysis incorporating the information
about adverse reactions after vaccinia vaccination because of sample
size limitations.
In a ®nal step we analyzed the consistency of ®ndings over
the 11 study centers. Because of small sample sizes in two of
the three participating institutions from former West Germany
we combined the samples from GoÈttingen (53 cases, 52
controls), Hamburg (11 cases, 11 controls), and Berlin-West
(six cases, six controls). Additionally, data from the two
neighboring Italian centers at Padova (55 cases, 60 controls)
and Verona (44 cases, 44 controls) have been collapsed to one
study region. Formal testing of homogeneity of the OR across
the eight study regions by the DerSimonian and Laird method
yielded nonsigni®cant p-values larger than 0.3 in all situations.
A closer look at the individual results revealed that data from
the small French center at Dijon (55 cases, 59 controls) were at
con¯ict with the overall picture. At Dijon the vaccinia
vaccination was not associated with a signi®cantly lower
melanoma risk (OR = 0.82, 95% CI: 0.26±2.57) and the
relationship between BCG vaccination and melanoma risk was
even inverse to the others (OR = 1.96, 95% CI: 0.63±6.62).
Similar anomalous results also emerged from the joint analysis of
vaccinations in the French center.
DISCUSSION
Overall, our analyses of the FEBIM data point to a rather strong
inverse association between melanoma and previous vaccinations
against tuberculosis and smallpox. As this study is the ®rst one
suggesting such a relationship, careful consideration of the internal
consistency of ®ndings, the limitations of the study, and how these
results ®t into current knowledge about melanoma etiology is
necessary before drawing causal conclusions from this ®nding.
The pronounced risk-lowering effect of BCG and vaccinia
vaccinations can be consistently found in the entire sample, in the
two strata de®ned by gender and in almost all individual study
centers. A possible explanation for the different results in the
French center concerning the effect of BCG vaccination is that
daughter strains of BCG used in France may have different
immunologic effects. Differences in BCG daughter strains is one of
a number of postulated explanations of why protection against
tuberculosis conferred by BCG varies so much from region to
region (Comstock, 1988). This possibility requires further detailed
investigation.
The discrepancy of ®ndings among younger and older study
subjects even supports the hypothesis of a causal relationship
between vaccinations and the prevention of melanoma. According
to the well-known time-dependent fading of the protection
afforded by both vaccines (Colditz et al, 1994; Henderson and
Moss, 1999) a stronger effect in younger persons is to be expected.
For older persons the clear weakening of the inverse association for
single vaccinations as well as the more distinct effect of the
combination of both vaccinations ®t into the expected pattern of
empirical ®ndings indicative of a causal relationship.
Similarly, the difference of results between the analyses of the
two case groups of ``thin'' (< 1.5 mm) and ``thick'' (> 1.5 mm)
melanomas can be interpreted as corroborating a causal hypothesis.
If the vaccinations under study were to show some protective effect
on melanoma initiation and progression by speci®c immunologic
mechanisms (see later), then comparing controls with more
advanced cases (the group of thick melanomas) should lead to
clearer results than the comparison with early cases (the group of
thin melanomas). Although Breslow's tumor thickness is a very
strong predictor of the prognosis of melanoma cases, the mere
knowledge of the Breslow value irrespective of the tumor's
histopathology does not give a reliable clue to the time period since
the onset of the tumor. Therefore, the distinction of early and more
advanced melanoma cases based on this tumor parameter alone is
not very accurate. Consequently, the results of the analyses of the
two distinct case groups are less different than one might expect,
but point consistently in the postulated direction. A more accurate
analysis of this aspect by considering tumor thickness within
subgroups de®ned by histopathology of the tumor could not be
undertaken due to sample size limitations.
One potential explanation for new epidemiologic ®ndings is
always the presence of some form of uncontrolled bias leading to
spurious associations. Thus, we address the issues of selection bias,
information bias, and confounding in detail below.
It seems unlikely to us that the sampling of FEBIM study
participants suffered from selection bias. Incident melanoma cases
were enrolled based on hospital registers shortly after their
diagnosis. Most participating centers serve as the only hospital for
melanoma patients in their catchment area (except Hamburg and
Berlin). Thus, the case sample can be viewed as being represen-
tative of melanoma cases in the population. This assertion has been
veri®ed by comparing the center-speci®c case samples with data
from the local cancer registries showing similar distributions of
tumor characteristics in melanoma cases enrolled in the FEBIM
study and registered in the corresponding catchment area. The
controls were also recruited from the population without imposing
any restrictions on them other than those given by the frequency-
matching procedure. The response rates for both groups were
above 80%. Overall, we feel that selection bias is an implausible
explanation for our ®ndings.
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Exposure misclassi®cation is a severe problem in all epidemio-
logic studies relying on the study subjects' recollection of events
early in life. For the special context of melanoma epidemiology,
empirical evidence concerning magnitude and direction of
misclassi®cation is rather limited, even for established risk factors
of melanoma (Weinstock et al, 1991; Gefeller and Brenner, 1996;
Cockburn et al, 2001). The ascertainment of the vaccination status
is most accurate for the subsample of study subjects where
vaccination cards were available at the time of the interview. For
the majority of subjects, however, this documentation was missing
and the persons' memory had to be accepted as an error-prone
source of information. In the FEBIM study special attention was
paid to this problem in the standardized instructions for interview-
ers how to conduct the interviews and during their pre-trial
training in which all FEBIM procedures were explained to them.
Adequate time was devoted to the assessment of the study subjects'
vaccination histories during a personal interview at their homes.
Despite these efforts, misclassi®cation of exposure information will
have affected our data. There are, however, no reasons to assume
that this form of information bias will have operated differentially
between cases and controls. Neither interviewers nor study subjects
were aware of the study hypothesis; thus, interviewer or recall bias
is unlikely. It is therefore reasonable to assume that we have to face
nondifferential exposure misclassi®cation, whichÐexcept in rare
circumstances (Dosemeci et al, 1990)Ðleads to some bias towards
the null, meaning that the true protective effect of BCG and
vaccinia vaccination is even stronger than estimated in this study.
Confounding by other risk factors for melanoma as a possibility
for producing spurious associations can never be ruled out
completely. In the FEBIM study we have carefully ascertained
information on known risk factors such as skin type, freckling
index, number of nevi, and exposure to UVR. Out of a number of
UVR-related exposure indicators we have selected the number of
sunburns as the variable used in the analysis. This decision is in
accordance with the practice adopted in many (but not all) case±
control studies in this area and is founded on the belief that
sunburns as an indicator of excessive intermittent exposure to UVR
are more reliably remembered over long periods of time than other
UVR-related variables (Cockburn et al, 2001).
In logistic regression models the confounding effect of all these
variables and the factors utilized in the frequency matching (study
center, sex, age, ethnic origin) has been controlled for when
estimating the impact of the vaccinations on melanoma risk. Of
course, unknown melanoma risk factors might have confounded
the analysis, but these factors need to be risk factors at least as strong
as the vaccinations under study to explain the observed results. We
believe that this is more a theoretical possibility than a real threat to
the validity of our ®ndings.
The immunologic aspects of the underlying mechanisms of
melanoma initiation and progression are currently a rapidly
evolving area of research (Nesbit et al, 1998). To discuss in
suf®cient immunologic detail the role of BCG and vaccinia
vaccinations in this process is beyond the scope of this paper.
Brie¯y, both BCG and vaccinia vaccinations induce a type 1
cytokine response that leads to macrophage activation (Ramshaw et
al, 1997; Ravn et al, 1997; Smith et al, 1997). Laboratory
experiments have shown a strong tumor-destructive effect of this
type of immune response on melanoma cells (Fujimoto et al, 1996).
The discrepancy between these laboratory ®ndings and unsuccessful
earlier attempts to treat melanoma with BCG and vaccinia
vaccinations may be explained by the timing of the vaccination.
``Natural'' vaccinations against tuberculosis and smallpox are
applied early in life, whereas therapeutic vaccinations are admin-
istered much later. At least for BCG there is experimental evidence
that the immune reaction of vaccinated subjects changes with their
age depending on prior environmental sensitization (Rosenthal,
1986; Grange et al, 1995). As a consequence, a vaccination with
BCG after previous imprinting of the immune system by envir-
onmental mycobacteria may stimulate a type 2 cytokine response
pattern (Bretscher, 1992) and thus be of limited value for tumor
destruction (Stanford et al, 1999). The disappointing experience
with BCG and vaccinia vaccination as therapeutic agents in the
treatment of melanoma patients does therefore not con¯ict with
our epidemiologic results that seem to ®t into current immunologic
theory.
Epidemiologic evidence of an inverse association between BCG
vaccination and cancer risk (other than melanoma) has also been
accumulated to some extent. Especially for juvenile leukemia, a
remarkable risk reduction among BCG-vaccinated children was
repeatedly found in several studies (reviewed in Grange and
Stanford, 1990). The impact of vaccinia vaccination on cancer
development was, however, addressed only in one very small study
on rhabdomyosarcoma (Grufferman et al, 1982).
In conclusion, we observed a strong protective effect of BCG
and vaccinia vaccinations on melanoma risk in a large, population-
based, case±control study that is unlikely to be the mere
consequence of some form of bias and that ®ts into the current
immunologic understanding of melanoma initiation and progres-
sion. If our results are con®rmed by future studies, vaccination
strategies for the prevention of melanoma will require careful
consideration. Although it is unlikely that vaccinia vaccination will
be reintroduced, unless as a carrier for new generations of subunit
vaccines, the case seems to be different for BCG vaccination. In
view of the rising incidence of tuberculosis, including multidrug-
resistant forms, the case for widespread neonatal BCG vaccination
becomes an increasingly strong one, if the melanoma preventive
effect is additionally considered.
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